Michael Szarek, PhD, on Treatment Advances With Tivozanib for RCC Going Forward

In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, spoke about where he believes renal cell carcinoma treatment will advance in the coming years.

Transcription:

Tivozanib [Fotivda] is a [tyrosine kinase inhibitor]. There are a lot of different drugs that are approved for renal cell carcinoma. One of the future [prospects] is obviously for the PD-1 class to move into renal cell carcinoma more and more. Combinations with PD-1 [inhibitors] is one area. Hopefully, if tivozanib is approved, then I think other sponsors and perhaps the sponsor of the drug itself will look into combining it with other agents including [PD-1 inhibitors]. So that’s one likely future avenue for the treatment of renal cell carcinoma.